“Liquid Biopsy” – Is it a Feasible Option in Colorectal Cancer?

Viorel Scripcariu1,2, Dragoș-Viorel Scripcariu1,2, Bogdan Filip1,2, Mihaela-Mădălina Gavrilescu1,2, Ana-Maria Mușină1,2, Constantin Volovăț1

1Faculty of Medicine, ”Grigore T Popa” University of Medicine and Pharmacy, Iași, Romania
21st Surgical Oncology Unit, Regional Institute of Oncology, Iași, Romania

Corresponding author:
Dragoș-Viorel Scripcaru, MD
“Grigore T Popa” University of Medicine and Pharmacy
16 Universității street, Iași, Romania
E-mail: dscripcariu@gmail.com

Received: 02.03.2019
Accepted: 08.04.2019

Rezumat

“Biopsia lichidă” – o opțiune fezabilă în cancerul colorectal?

Este important pentru chirurg să țină pasul cu noutățile atât din, cât și din afara sferei lor de activitate. Pe măsură ce medicina evoluează, apar noi tehnici, iar oncologia este unul dintre principalii beneficiari ai lor. "Biopsia lichidă” reprezintă unul dintre cele mai recente domenii de interes în oncologie, deoarece poate oferi detalii importante privind caracteristicile tumorii primare și ale metastazelor sale. Celulele maligne se află într-o dinamică continuă, ceea ce face ca biopsia inițială, din momentul diagnosticului, dar și evaluarea piesei anatomopatologice să fie insuficiente în evoluția târzie a bolii, când pot apărea recidive sau metastaze. Faptul că furnizorul de servicii medicale este capabil să găsească informații suplimentare despre tumoră la un moment dat prin evaluarea unei probe de sânge pentru a obține o "biopsie lichidă” este de cea mai mare importanță și oferă date multiple potențial utilizabile. Există trei modalități de obținere a unui material biologic care poate fi folosit ca "biopsie lichidă”: evaluarea celulelor tumorale circulante, a ADN-ului tumoral circulant și a exosomilor. Entitatea cea mai intens studiată este aceea a celulelor tumorale circulante, cu aplicații diferite, dintre care cea mai importantă, în prezent, este valoarea prognostică, aceasta având implicații importante, nu numai în cancerul de sân și prostată, dar și în cancerul colorectal. Deși chirurgia nu va fi înlocuită de alte tratamente atunci când vine vorba de o abordare curativă a cancerului rectal, este important pentru chirurg să cunoașcă informații despre domenii complementare, unul din acestea fiind al "biopsiei lichide".
As medicine evolves, the approach to colorectal cancer becomes more and more based on the multidisciplinary team. One of the emerging topics in oncology is about “liquid biopsy”, that shows more and more applications and proves to be useful in multiple types of cancer. Tumors have an important feature that hinders the efficacy of radiotherapy, chemotherapy or targeted therapy, which is genetic heterogeneity (1). Thus, the more information clinicians can get about the tumor, the better and more targeted the treatment will be.

On the other hand, one of the most important prognostic factors in colorectal cancer and the main decision factor that guides chemotherapy is the presence of metastatic disease (2,3). This issue may appear at the initial presentation, after neo-adjuvant treatment (when applicable), or during evolution after surgery.

These are just two of the reasons why the biopsy and the surgical specimen in colorectal cancer are slowly becoming insufficient if we are aiming for an efficient, tailored approach for each patient. In the last two decades, the detection of circulating tumor cells (CTCs) in the peripheral blood flow of the patient has shown to provide important information about the main tumor or its metastases. Because of the apparition of apoptosis of said CTCs, intracellular components are released into the bloodstream, constituting circulating tumor materials: circulating tumor DNA (ctDNA) and exosomes (4). The aforementioned three entities constitute the sources for “liquid biopsy” in cancer and may become important biomarkers for the prognostic and monitoring of neoplastic disease.

CTCs are cells released in the bloodstream from the main tumor. The first documented mention of this entity is in 1869, by Thomas Ashworth, a pathologist from Melbourne, Australia, who identified multiple atypical cells...
in a post-mortem blood sample from a patient dying of cancer, classifying them as tumor cells that may have been held accountable for multiple tumors disseminated throughout the patient’s body (5). However, this subject was not approached until in the 1970’s, when it became increasingly popular within the research community, with constantly growing numbers of articles approaching the issue of CTCs (6).

In order to become circulant, tumor cells have to undergo several phenotypic changes, known as the epithelial-mesenchymal transition, through which cells are enabled to detach from and migrate through the basal membrane, thus having the possibility to be released into the blood-flow and be carried to secondary sites and metastasize. These cells may circulate single or in homogenous or heterogenous clusters, with increased chances of “survival” and reaching the target organs (7).

CTCs are rare even in the blood of patients with metastatic disease and are hard to find in a background of blood cells (8); it has been demonstrated that there is approximately one CTC to every $10^6$-$10^7$ circulating mononuclear cells (9), although these numbers may vary in accordance to the stage of the neoplastic disease. These aspects lead us to realize the difficulty of isolating CTCs in the patient’s peripheral blood: on the one hand, it is hard to identify CTCs due to the low number of such cells in circulation and on the other hand, it is difficult to separate these cells from other circulating blood cells.

Thus, different strategies have been imagined in order to identify CTCs, but all strategies have in common two targets: isolation and detection. Isolation, or enrichment techniques are based upon two approaches: selection by immunologic profile – expression of cell surface proteins such as EpCAM (epithelial cell adhesion molecule), or by morphological characteristics - density, size, electric charge. Isolation usually leads to obtaining a solution that contains a combination of CTCs and leukocytes, requiring further processing in order to select the targeted cells: identification, or detection means immuno- histochemistry or PCR, RT-PCR (10).

There are many techniques to identify circulating tumor cells: however, the only FDA-certified and the one used to obtain most of the clinical data at present time in colorectal cancer is CellSearch (Janssen Diagnostics) (10), which consists of an affinity-based assessment of 7.5 ml of blood.

There are multiple applications of CTCs in neoplasia in general and in colorectal cancer in particular, as these cells have been more intensively studied in breast cancer, followed by prostate and colorectal cancer (11). The utility of examining CTCs in colorectal cancer patients can be seen from the following points of view (12):
1. as a screening instrument;
2. for diagnostics;
3. as predictive factors for orienting the treatment;
4. as prognostic factors;
5. for guiding and assessing the treatment;
6. as a follow-up tool.

Bearing in mind the above-mentioned low number of CTCs, the utility of evaluating these cells as a screening instrument is yet to be made possible by the availability of instruments for in vivo evaluation (such as CellCollector) (12).

The utility as a diagnostic tool is, as well, to be demonstrated: as aforementioned, by providing important information about the main tumor or its metastases, CTCs may be considered an important companion for a complete diagnostic of the cancer and may be used as a tool of guiding anti-cancer therapies (13). Thus, prognosis of response to treatment may be one additional application of CTCs: it was to date studied in breast cancer, through a phase III clinical trial – the SWOG S0500 trial (14), that evaluated the number of CTCs before, during and after chemotherapy, but was only able to conclude that a large cell-count at the beginning and during chemotherapy is associated with worse survival, with no significant impact on response to chemotherapy. This application would be of great utility for rectal cancer in prediction of response to neoadjuvant treatment or even prediction for the appearance of metastatic disease during or after neoadjuvant treatment. No studies of this
kind are, to date, present in literature.

The most important application and the only validated one through studies is the prognostic value of CTCs. As above-mentioned, clinical studies in breast cancer set a cutoff value of 5 CTCs in 7.5 ml of peripheral blood of the newly-diagnosed patient as a predictive factor for impaired disease-free survival and overall survival (15). In addition, the 8th edition of the TNM Classification includes the presence of CTCs in the patient’s blood in breast cancer as a separate, M0(i+) staging, with possible impact on therapeutic approach (16). This aspect has been studied in colorectal cancer as well, studies setting a cutoff value of 3 CTCs per 7.5 ml of blood as a negative prognostic factor for the patient’s survival (17).

Another significant element in the discussion about “liquid biopsy” is ctDNA, which may come from apoptotic or necrotic tumor cells, or may be released into circulation by living tumor cells (18,19).

In cancer patients, the study of ctDNA may have several utilities, such as detection of residual disease after radical surgery as a negative prognostic factor, monitoring of tumor burden – increases in ctDNA may mean disease progression, monitoring of appearance of tumor molecular resistance – guiding therapy in certain patients, or even early detection of certain tumors (20).

Last but not least, exosomes are considered important biomarkers for tumor burden and metastasis and they are abundant in peripheral blood of patients. The study of exosomes is particularly interesting for the oncologist as they are stable carriers of genetic material and proteins from their cell of origin (20).

In conclusion, we see that in a world with constant evolution of the approach to neoplasia, multidisciplinarity is of utmost importance and it is useful for the general surgeon to be up-to-date with concepts that may, in the near future, change the way we treat cancer. Although in a very early stage of its existence and in high need of validation, “liquid biopsy” may represent in the future a useful tool of diagnosis, prognosis and follow-up in colorectal cancer. The constantly increasing number of articles on this topic found in literature endorses this idea; in addition, the lower invasiveness of the procedure may represent one more argument for the rise if this technique.

At the time being, surgery is in no danger of becoming futile in colorectal cancer; we must understand the importance of a tailored approach to each cancer patient and the significant advances in medicine that make the work of the multidisciplinary team more and more efficient.

Conflict of Interest

The authors declare no conflicts of interests.

References

5. Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aus Med J 1869;14:146-9.


